Literature DB >> 19541686

The spectrum of structural abnormalities on CT scans from patients with CF with severe advanced lung disease.

M Loeve1, P Th W van Hal, P Robinson, P A de Jong, M H Lequin, W C Hop, T J Williams, G D Nossent, H A Tiddens.   

Abstract

RATIONALE: In cystic fibrosis (CF), lung disease is the predominant cause of morbidity and mortality. Little is known about the spectrum of structural abnormalities on CT scans from patients with CF with severe advanced lung disease (SALD). No specific CT scoring system for SALD is available.
OBJECTIVES: To design a quantitative CT scoring system for SALD, to determine the spectrum of structural abnormalities in patients with SALD and to correlate the SALD system with an existing scoring system for mild CF lung disease and pulmonary function tests (PFTs).
METHODS: 57 patients with CF contributed one CT made during screening for lung transplantation. For the SALD system, lung tissue was divided into four components: infection/inflammation (including bronchiectasis, airway wall thickening, mucus and consolidations), air trapping/hypoperfusion, bulla/cysts and normal/hyperperfused tissue. The volume proportion of the components was estimated on a 0-100% scale; mean volumes for the whole lung were computed. Scores were correlated with Brody-II scores and PFTs.
RESULTS: The SALD system identified a wide spectrum of structural abnormalities ranging from predominantly infection/inflammation to predominantly air trapping/hypoperfusion. SALD infection/inflammation scores correlated with Brody-II scores (r(s) = 0.36-0.64) and SALD normal/hyperperfusion scores correlated with forced expiratory volume in 1 s (FEV(1); r(s) = 0.37). Reproducibility for both systems was good.
CONCLUSIONS: A CT scoring system was developed to characterise the structural abnormalities in patients with SALD. A wide spectrum was observed in SALD, ranging from predominantly air trapping to predominantly infection/inflammation-related changes. This spectrum may have clinical implications for patients with SALD.

Entities:  

Mesh:

Year:  2009        PMID: 19541686     DOI: 10.1136/thx.2008.110908

Source DB:  PubMed          Journal:  Thorax        ISSN: 0040-6376            Impact factor:   9.139


  16 in total

Review 1.  Chest imaging in cystic fibrosis studies: What counts, and can be counted?

Authors:  Rhonda Szczesniak; Lidija Turkovic; Eleni-Rosalina Andrinopoulou; Harm A W M Tiddens
Journal:  J Cyst Fibros       Date:  2016-12-28       Impact factor: 5.482

Review 2.  Diagnostic radiology in paediatric palliative care.

Authors:  Preena Patel; Michelle Koh; Lucinda Carr; Kieran McHugh
Journal:  Pediatr Radiol       Date:  2014-01-07

3.  Assessment of CF lung disease using motion corrected PROPELLER MRI: a comparison with CT.

Authors:  Pierluigi Ciet; Goffredo Serra; Silvia Bertolo; Sandra Spronk; Mirco Ros; Francesco Fraioli; Serena Quattrucci; M Baroukh Assael; Carlo Catalano; Fabio Pomerri; Harm A W M Tiddens; Giovanni Morana
Journal:  Eur Radiol       Date:  2015-05-30       Impact factor: 5.315

Review 4.  What did we learn from two decades of chest computed tomography in cystic fibrosis?

Authors:  Harm A W M Tiddens; Tim Rosenow
Journal:  Pediatr Radiol       Date:  2014-08-28

Review 5.  Scoring of chest CT in children with cystic fibrosis: state of the art.

Authors:  Alistair D Calder; Andrew Bush; Alan S Brody; Catherine M Owens
Journal:  Pediatr Radiol       Date:  2014-08-28

Review 6.  Novel end points for clinical trials in young children with cystic fibrosis.

Authors:  Shannon J Simpson; Lauren S Mott; Charles R Esther; Stephen M Stick; Graham L Hall
Journal:  Expert Rev Respir Med       Date:  2013-06       Impact factor: 3.772

7.  Emphysema Is Common in Lungs of Cystic Fibrosis Lung Transplantation Patients: A Histopathological and Computed Tomography Study.

Authors:  Onno M Mets; Suzan M Roothaan; Inez Bronsveld; Bart Luijk; Ed A van de Graaf; Aryan Vink; Pim A de Jong
Journal:  PLoS One       Date:  2015-06-05       Impact factor: 3.240

Review 8.  Novel outcome measures for clinical trials in cystic fibrosis.

Authors:  Harm A W M Tiddens; Michael Puderbach; Jose G Venegas; Felix Ratjen; Scott H Donaldson; Stephanie D Davis; Steven M Rowe; Scott D Sagel; Mark Higgins; David A Waltz
Journal:  Pediatr Pulmonol       Date:  2014-12-30

9.  Patient-specific modeling of regional antibiotic concentration levels in airways of patients with cystic fibrosis: are we dosing high enough?

Authors:  Aukje C Bos; Cedric van Holsbeke; Jan W de Backer; Mireille van Westreenen; Hettie M Janssens; Wim G Vos; Harm A W M Tiddens
Journal:  PLoS One       Date:  2015-03-03       Impact factor: 3.240

Review 10.  Bronchoscopy-guided antimicrobial therapy for cystic fibrosis.

Authors:  Kamini Jain; Claire Wainwright; Alan R Smyth
Journal:  Cochrane Database Syst Rev       Date:  2018-09-17
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.